Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection

FEMS Immunology and Medical Microbiology

Volumn 33, Issue 3, 2002, Pages 219-225

  Watanabe, Mineo ^a   Komatsu, Eiji ^b   Sato, Takaaki ^b   Nagai, Masaaki ^b  

^a DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^b KITASATO INSTITUTE   (Japan)

Author keywords

Acellular pertussis vaccine; Aerosol challenge model; DPT vaccine; Intracerebral challenge model; Kendrick test

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA VACCINE; GAMMA INTERFERON; HEMAGGLUTININ; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TETANUS TOXOID;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; FEMALE; FIMBRIA; IMMUNIZATION; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT INFECTION; SPLEEN CELL; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON TYPE II; MICE; PERTUSSIS VACCINE; SPLEEN; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 0037067629     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(02)00323-1     Document Type: Article

References (30)

1. Pertussis vaccine
2. Result with a new DTP vaccine in Japan
3. Development of a pertussis component vaccine in Japan
4. Type-specific efficacy of acellular pertussis vaccine
5. Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age
6. Current epidemiology of pertussis in Japan
7. Pertussis vaccines in Japan
8. Overview of currently available Japanese acellular pertussis vaccines and future problems
9. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by six Japanese manufacturers
10. Clinical studies on efficacy and safety of acellular pertussis vaccine
11. Mouse protection tests in the study of pertussis vaccine: A comparative series using the intracerebral route of challenge
12. Informal consulting with manufacturers and WHO Ad Hoc working group on mouse protection models for acellular pertussis vaccines
13. Evolution of control testing of pertussis vaccine
14. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines
15. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: Value of laboratory tests as predictors of clinical performance
16. Efficacy of chemical cross-linked antigens for acellular pertussis vaccine
17. Interaction of the Bordetella pertussis filamentous hemagglutinin with heparin
18. Single-step purification of pertussis toxin and its subunits by heat-treated fetuin-Sepharose affinity chromatography
19. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase
20. Purification and analysis of the antigenicity of a 69,000 Da protein from Bordetella pertussis
21. Purification and characterization of serotype 6 fimbriae from Bordetella pertussis and comparison of their properties with serotype 2 fimbriae
22. Serospecific protection of mice against intranasal infection with Bordetella pertussis
23. Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model
24. Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice
25. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection
26. Interferon-gamma induction by lipopolysaccharide: Dependence on interleukin-2 and macrophages
27. Induction of a specific antibody response to Bordetella pertussis antigens in cultures of human peripheral blood mononuclear cells
28. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis
29. Comparison of 13 acellular pertussis vaccines: Overview and serologic response
30. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity